Novartis at Festival of Biologics 2026
Oct 13–15, 2026 Basel, Switzerland ~3k attendees Website
Novartis takes part in 32 sessions at Festival of Biologics 2026 in Basel, its home city, and exhibits at Booth 185. Its program spans the whole path of a biologic, from antibody formats and AI tools to cell line development, purification, bioanalysis and gene therapy. Distinctive topics include a cattle-derived AAV vector for lung gene therapy and AI that predicts whether a biologic will trigger an immune response.
| Organization | Festival of Biologics 2026 Attendance |
|---|---|
Novartis Basel, Switzerland | |
Global pharmaceutical company whose contract manufacturing arm offers CDMO services for biologics, small molecules, cell and gene therapy, and fill-finish. | Booth Exhibiting at Booth 185 Keynote Tue Oct 13 09:10 Biotechnology, the Renaissance How advances in biology, AI and new treatment types are converging to change what medicine can do for patients. Chair Tue Oct 13 11:25 Chair Tue Oct 13 11:25 Chair Tue Oct 13 11:25 Talk Tue Oct 13 11:30 Panel Tue Oct 13 12:20 Chair Tue Oct 13 14:05 Talk Tue Oct 13 14:50 Intensified Upstream Processing: Fed‑Batch and Perfusion Options for Robust Scale-Up Ways to get more protein from cell cultures by feeding them steadily or continuously, and how to scale that up reliably. Talk Tue Oct 13 15:10 Panel Tue Oct 13 15:10 Panel Discussion: From Research to GMP: Making MSC Manufacturing Reproducible at Scale How to grow mesenchymal stromal cells, a kind of stem cell, the same way batch after batch as production scales up. Talk Tue Oct 13 15:30 Chair Tue Oct 13 16:45 Panel Tue Oct 13 17:30 Panel Discussion: Next Generation Antibody Formats Where antibody drug design is heading, from two-target antibodies and antibody-drug conjugates to AI's role in engineering them. Talk Tue Oct 13 17:30 What AI can do – or not – in Patient Engagement What AI can and cannot do when drug developers involve patients in research, and how to measure whether that involvement helps. Chair Wed Oct 14 11:25 Chair Wed Oct 14 11:25 Talk Wed Oct 14 12:10 Talk Wed Oct 14 12:30 Bovine AAV – a promising vector for pulmonary gene therapy Early results from using a cattle adeno-associated virus to deliver gene therapy to the lungs, including how immune systems recognise it. Talk Wed Oct 14 12:30 Chair Wed Oct 14 14:05 Talk Wed Oct 14 14:30 Commercial Considerations for CAR-T Therapy: Lessons Learned from Recent Blockbusters What makes CAR-T cancer therapies hard to sell worldwide, from complex manufacturing and shipping to getting treatment centres and payers ready. Talk Wed Oct 14 15:30 When the Target Moves: Building Robust DSP Through Science, Monitoring, and Learning Why purification steps that once worked can start failing when the material feeding them changes, and how monitoring catches that early. Chair Wed Oct 14 16:45 Chair Wed Oct 14 16:45 Talk Wed Oct 14 16:50 Talk Wed Oct 14 17:30 Protein Quality as a Critical Factor in Target Interference Assessment for Bioanalytical Assays How the quality of a lab-made protein can distort tests that check whether patients make antibodies against a biologic drug. Talk Wed Oct 14 17:50 An Oligonucleotide Program in Late-Stage Clinical Trials Lessons from keeping an anti-drug antibody test working for a cholesterol-lowering siRNA drug through late trials and a handover to a partner lab. Keynote Thu Oct 15 09:05 From Strategy to Delivery: Aligning Bioanalytical Innovation and Execution Across Clinical Phases How to decide what to measure, when and why, as biologic drugs move from early studies into late-stage clinical trials. Talk Thu Oct 15 09:40 Chair Thu Oct 15 11:15 Chair Thu Oct 15 11:15 |
Instantly find 20 buyers from Novartis
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by Terrapinn or the Festival of Biologics. Submit a correction